Alvotech to Acquire Xbrane Biopharma's R&D Operations, Biosimilar Candidate

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Alvotech to Acquire Xbrane Biopharma's R&D Operations, Biosimilar Candidate

, MT Newswires - 4:27 AM ET 3/20/2025 mergers-and-acquisitions

04:27 AM EDT, 03/20/2025 (MT Newswires) -- Alvotech ( ALVO ) said Thursday it is acquiring Xbrane Biopharma's R&D operations and biosimilar candidate XB003 for about 275 million Swedish krona ($27.2 million).

The acquisition, which is expected to close in April, includes Xbrane's R&D operations in Campus Solna, Sweden. Xbrane will retain other pre-clinical assets.

Alvotech ( ALVO ) also said it plans to explore a potential listing of Swedish depository receipts on Nasdaq Stockholm in the future.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.